Emotion suppression (also known as flat affect, apathy, or emotional blunting) is medically recognized as a flattening or decrease in the intensity of one's current emotional state below normal levels. This dulls or suppresses the genuine emotions that a person was already feeling prior to ingesting the drug. For example, an individual who is currently feeling somewhat anxious or emotionally unstable may begin to feel very apathetic, neutral, uncaring, and emotionally blank. This also impacts the degree to which the person will express their emotional state through body language, tone of voice, and facial expressions.
It is worth noting that although a reduction in the intensity of one's emotions may be beneficial at times (e.g., the blunting of an anger response in a volatile patient), it may be detrimental at other times (e.g., emotional indifference at the funeral of a close family member).
Emotion suppression is often accompanied by other coinciding effects such as motivation suppression, thought deceleration, and analysis suppression. It is most commonly induced under the influence of moderate dosages of antipsychotic compounds, such as quetiapine, haloperidol, and risperidone. However, it can also occur in less consistent form under the influence of heavy dosages of dissociatives, SSRI's, and GABAergic depressants.
Substances which may cause this effect include:
- Selective serotonin reuptake inhibitor
Anecdotal reports which describe this effect within our experience index include:
- Experience:1.2 g gabapentin, alcohol, and half of 150 mg Effexor XR - Pretty lovely for socializing and giggles
- Experience:100-350mg - Phenylpiracetam in daily life
- Experience:2C-P (approx. 35mg) - Asymmetrical Terror and the Geometric Sea
- Experience:3-MMC: Weak substitute? No way!
- Experience:3mg Etizolam - A Comedown Drug
- Experience:Nutmeg (8 teaspoons) - My Mom Introduces Me To Genesis and Other Things
- Experience:Unknown Dose DOC (Insufflated) - Overdosing and Terifying Ego Death
- ↑ 1.0 1.1 Ueda, Satoshi; Sakayori, Takeshi; Omori, Ataru; Fukuta, Hajime; Kobayashi, Takashi; Ishizaka, Kousuke; Saijo, Tomoyuki; Okubo, Yoshiro (2016). "Neuroleptic-induced deficit syndrome in bipolar disorder with psychosis". Neuropsychiatric Disease and Treatment: 265. doi:10.2147/NDT.S99577. ISSN 1178-2021.
- ↑ "Neurocognitive Disorders". Diagnostic and statistical manual of mental disorders (5th ed.): 609. 2013. doi:10.1176/appi.books.9780890425596.dsm17.
- ↑ Gur, R. E; Kohler, C. G; Ragland, J D.; Siegel, S. J; Lesko, K.; Bilker, W. B; Gur, R. C (2006). "Flat Affect in Schizophrenia: Relation to Emotion Processing and Neurocognitive Measures". Schizophrenia Bulletin. 32 (2): 279–287. doi:10.1093/schbul/sbj041. ISSN 0586-7614.
- ↑ 4.0 4.1 Sansone, R. A., Sansone, L. A. (October 2010). "SSRI-Induced Indifference". Psychiatry (Edgmont (Pa.: Township)). 7 (10): 14–18. ISSN 1555-5194.
- ↑ Moncrieff, J.; Cohen, D.; Mason, J. P. (2009). "The subjective experience of taking antipsychotic medication: a content analysis of Internet data". Acta Psychiatrica Scandinavica. 120 (2): 102–111. doi:10.1111/j.1600-0447.2009.01356.x. ISSN 0001-690X.
- ↑ Vollenweider, F. X. (31 December 2001). "Brain mechanisms of hallucinogens and entactogens". Dialogues in Clinical Neuroscience. 3 (4): 265–279. doi:10.31887/DCNS.2001.3.4/fxvollenweider. ISSN 1958-5969.
- ↑ Micallef, J; Tardieu, S; Gentile, S; Fakra, E; Jouve, E; Sambuc, R; Blin, O (2003). "Évaluation psychocomportementale de l'administration de faible dose de kétamine chez le sujet sain". Neurophysiologie Clinique/Clinical Neurophysiology. 33 (3): 138–147. doi:10.1016/S0987-7053(03)00028-5. ISSN 0987-7053.
- ↑ Bolling, Madelon Y.; Kohlenberg, Robert J. (2004). "Reasons for Quitting Serotonin Reuptake Inhibitor Therapy: Paradoxical Psychological Side Effects and Patient Satisfaction". Psychotherapy and Psychosomatics. 73 (6): 380–385. doi:10.1159/000080392. ISSN 0033-3190.
- ↑ Oscar-Berman, M., Bowirrat, A. (September 2005). "Genetic influences in emotional dysfunction and alcoholism-related brain damage". Neuropsychiatric Disease and Treatment. 1 (3): 211–229. ISSN 1176-6328.